Following preoperative chemoradiation for T3N1 rectal cancer, the incidence of viable nodal disease in patients who achieve a ypT0 response in the rectal wall is:
There's more to see -- the rest of this topic is available only to subscribers.
"Post-Test 38." Fundamentals of Rectal Cancer Surgery, ASCRS U, www.ascrsu.com/ascrs/view/Fundamentals-of-Rectal-Cancer-Surgery/2831069/all/Post_Test_38. Accessed 04 June 2023.
Post-Test 38. Fundamentals of Rectal Cancer Surgery. https://www.ascrsu.com/ascrs/view/Fundamentals-of-Rectal-Cancer-Surgery/2831069/all/Post_Test_38. Accessed June 4, 2023.
Post-Test 38. In Fundamentals of Rectal Cancer Surgery https://www.ascrsu.com/ascrs/view/Fundamentals-of-Rectal-Cancer-Surgery/2831069/all/Post_Test_38
Post-Test 38 [Internet]. In: Fundamentals of Rectal Cancer Surgery. [cited 2023 June 04]. Available from: https://www.ascrsu.com/ascrs/view/Fundamentals-of-Rectal-Cancer-Surgery/2831069/all/Post_Test_38.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Post-Test 38 ID - 2831069 BT - Fundamentals of Rectal Cancer Surgery UR - https://www.ascrsu.com/ascrs/view/Fundamentals-of-Rectal-Cancer-Surgery/2831069/all/Post_Test_38 DB - ASCRS U DP - Unbound Medicine ER -